Interaction Between Nalbuphine and Morphine in PCA

Interaction Between Nalbuphine and Morphine in Postoperative PCA for Gynecologic Patients

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00155233

Enrollment

200

Registered

2005-09-12

Start date

2005-01-31

Completion date

Unknown

Last updated

2005-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

analgeisa, postoperatve, side effects

Brief summary

1. Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist 2. This study was designed to investigate the interaction between nalbuphine and morphine

Detailed description

1. Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist 2. This study was designed to investigate the interaction between nalbuphine and morphine 3. The analgesic effect and opioid-related side effects will be investigated

Interventions

DRUGNalbuphine and morphine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. Age 18-65 y/o 2. Female patients of ASA physical status I to III 3. Scheduled for elective abdominal hysterectomy, myomectomy, or excision of ovarian tumor

Exclusion criteria

1. Patients with a definite diagnosis of chronic pain syndrome, psychiatric disorders, or drug abuse (include opioids, NSAIDs, sedatives, antidepressants) 2. Intraoperative fentanyl use \> 3 μg/kg 3. Patients with definite diagnosis of esophageal reflux syndrome 4. Use of sedatives, antiemetics, or antipruritics within 24 hours before operation 5. Surgery \> 4 hours or laparoscopy surgery

Design outcomes

Primary

Measure	Time frame
analgesic effect	—

Secondary

Measure	Time frame
incidence of opioid-related side effects	—

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026